Skip to main content
Orexo logo

Orexo — Investor Relations & Filings

Ticker · ORX ISIN · SE0000736415 LEI · 549300LJ5CCWDPTK9Z08 ST Manufacturing
Open in API
Filings indexed 843 across all filing types
Latest filing 2009-10-06 Regulatory Filings
Country SE Sweden
Listing ST ORX

About Orexo

https://orexo.com/

Orexo is a commercial-stage pharmaceutical company focused on developing improved pharmaceuticals and digital therapies. The company addresses unmet patient needs, particularly within substance use disorders and mental health. It leverages proprietary drug delivery and formulation technologies to create innovative treatment solutions. Orexo's activities span research, development, and commercialization of its products.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2009
Regulatory Filings Classification · 1% confidence The document is a press release dated October 6, 2009, announcing that the New Drug Application (NDA) filing for the product Abstral has been accepted for review by the US FDA. This is a specific corporate update regarding regulatory progress and partnership activities related to a drug filing. It is not a full Annual Report (10-K), an Interim Report (IR), an Earnings Release (ER), or a formal shareholder vote announcement (AGM-R, DVA). While it relates to a product, it is primarily an announcement of a regulatory milestone. Given the options, this type of specific corporate news release, especially one concerning regulatory acceptance and partnership updates, fits best under the general 'Regulatory Filings' (RNS) category as a miscellaneous, non-standard filing, or potentially 'LTR' if interpreted as a legal/regulatory proceeding update, but RNS is the best fit for general corporate news not covered by other specific codes. Since it is a press release announcing a regulatory event, RNS (Regulatory Filings) is the most appropriate fallback, as there is no specific code for 'Regulatory Acceptance Announcement'.
2009-10-06 English
Regulatory Filings 2009
Regulatory Filings Classification · 1% confidence The document is a press release dated October 6, 2009, announcing that Orexo's partner, ProStrakan, has had its New Drug Application (NDA) for Abstral accepted for final review by the FDA. This is an announcement regarding a regulatory step (FDA acceptance) for a product, not the final approval, a full financial report (like 10-K or IR), or a general shareholder vote announcement. It is a specific corporate update concerning regulatory progress. Since it is a specific announcement that doesn't fit perfectly into the financial reporting categories (10-K, IR, ER, etc.), and it is a formal communication to the market, it best fits the general 'Regulatory Filings' category (RNS) as a catch-all for significant, non-standard corporate news, or potentially 'LTR' if viewed as a regulatory matter, but RNS is broader for general announcements. Given the context of a press release announcing a regulatory milestone, RNS is the most appropriate general classification for non-financial, non-management specific corporate news.
2009-10-06 Swedish
Major Shareholding Notification 2009
Major Shareholding Notification Classification · 1% confidence The document explicitly details a change in shareholding percentage and total shares held by 'HealthCap' in 'Orexo AB'. Key phrases like 'major shareholding notification', 'Before the transaction', 'After the transaction', and the reporting of 'Percentage' and 'Number of underlying shares' strongly indicate a filing related to significant ownership changes. This aligns directly with the definition for Major Shareholding Notification (MRQ). The document is short and appears to be the notification itself, not an announcement of a report.
2009-10-02 English
Declaration of Voting Results & Voting Rights Announcements 2009
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a short press release dated August 31, 2009, announcing a change in the total number of shares and votes for Orexo AB (publ). This change is explicitly linked to the second installment of a prior acquisition. This type of announcement, detailing changes in the total share count or capital structure, directly corresponds to the 'Share Issue/Capital Change' definition. Therefore, the appropriate code is SHA.
2009-08-31 English
Declaration of Voting Results & Voting Rights Announcements 2009
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a short press release dated August 31, 2009, announcing a change in the total number of shares and votes in Orexo AB (publ) due to a partial payment for an acquisition. This directly relates to a change in the company's capital structure (the number of outstanding shares). This aligns best with the 'Share Issue/Capital Change' definition (SHA), which covers changes in capital structure, including those resulting from corporate actions like acquisitions or payments involving share issuance. It is not a general regulatory filing (RNS) because it fits a more specific category, nor is it a dividend notice (DIV) or director dealing (DIRS). Given the short length and specific topic, SHA is the most appropriate classification.
2009-08-31 Swedish
Report Publication Announcement 2009
Report Publication Announcement Classification · 1% confidence The document is a press release dated August 28, 2009, announcing that Orexo has signed an exclusive worldwide licensing agreement with a Novartis affiliate for a novel formulation related to its OX17 program. This announcement details a significant business transaction involving intellectual property, future development funding, milestone payments, and royalties. This type of corporate action, which involves strategic partnerships, licensing, or major financing/deal structures, best fits the 'Capital/Financing Update' (CAP) category, as it directly impacts the company's future revenue streams and development pipeline structure. While it involves IP licensing, it is fundamentally a major business/financing deal announcement, rather than a general regulatory filing (RNS) or a specific M&A takeover (TAR). It is not an earnings release (ER), interim report (IR), or a formal presentation (IP).
2009-08-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.